InjectSense

Executive Summary

InjectSense is a San Francisco-based private company developing ultra-miniature implantable sensors for continuous, real-time monitoring of multiple physiological parameters, including absolute pressure, oxygenation, and motion. Founded in 2016, the company's self-anchoring platform is designed to provide 24/7 health insights to physicians, enabling proactive management of chronic conditions such as heart failure, hydrocephalus, and pulmonary diseases. By measuring key metrics directly inside the body, InjectSense aims to reduce hospital readmissions and improve patient outcomes through early detection of deterioration. The company's technology represents a significant advancement in digital health and drug delivery, with potential applications across a wide range of medical fields. While still in a developmental stage, InjectSense is likely pursuing regulatory clearances and strategic partnerships to commercialize its sensors. With a strong focus on minimally invasive, long-term monitoring, the company is well-positioned to address unmet needs in remote patient monitoring. However, as a private entity with limited public information, execution risks remain regarding clinical validation, manufacturing scalability, and market adoption.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for First Pressure Sensor45% success
• Q3 2026Series B Funding Round Completion70% success
• Q4 2026Strategic Partnership with Major Hospital Network for Clinical Trials55% success